Levetiracetam
Product Images NDC 50090-5495

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-5495). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905495)

Levetiracetam 1000 mg tablets packaging label from A-S Medication Solutions. The label states each tablet contains levetiracetam USP 1000 mg with 30 tablets per bottle. Storage instructions specify to keep at 68 to 77 degrees Fahrenheit. Includes product NDC 50090-5495 and lot number information. QR codes and manufacturer details for Eviva Pharma, Schaumburg, Illinois, are also visible.*

FDA Label Image

Levetiracitam Tablets, Usp-figure07 (Levetiracetam Tablets Usp 1)

A text panel showing formulas for calculating creatinine clearance (CLcr). It provides equations using age, weight, serum creatinine, and adjustments for female patients and body surface area (BSA). The formula includes factors for unit conversions and body surface area normalization.*

FDA Label Image

9596f2fe-figure-01 (Levetiracetam Tablets Usp 2)

Chemical structure of levetiracetam showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*

FDA Label Image

20 (Levetiracetam Tablets Usp 3)

A bar chart comparing the percentage of patients across three groups: Placebo (95 patients), Levetiracetam 1000 mg/day (97 patients), and Levetiracetam 3000 mg/day (101 patients). The chart shows the highest patient percentages for the Levetiracetam groups, with approximately 37.1% for 1000 mg/day and 39.6% for 3000 mg/day, compared to 7.4% for the placebo group. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

14 (Levetiracetam Tablets Usp 4)

Bar graph depicting the percentage of patients experiencing an unspecified outcome, comparing placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day groups. The Y-axis shows percentage of patients from 0% to 45%. Placebo group (N=111) shows 6.3%, Levetiracetam 1000 mg/day (N=106) shows 20.8%, and Levetiracetam 2000 mg/day (N=105) shows 35.2%.*

FDA Label Image

Levetiracetam Tablets Usp 5

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%. The graph highlights a higher percentage in the Levetiracetam group.*

FDA Label Image

54 (Levetiracetam Tablets Usp 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients. The Placebo group shows 19.6%, while the Levetiracetam group shows 44.6%, with an asterisk indicating significance.*

FDA Label Image

78 (Levetiracetam Tablets Usp 7)

A bar chart comparing the percentage of patients for Placebo (19.6%) and Levetiracetam (43.1%). The y-axis shows the percentage of patients ranging from 0% to 45%. Levetiracetam bar is higher and marked with an asterisk indicating statistical significance versus placebo. The sample sizes are N=51 for Placebo and N=58 for Levetiracetam.*

FDA Label Image

10 (Levetiracetam Tablets Usp 8)

A bar graph comparing the percentage of patients between two groups: Placebo (N=84) with 45.2%, and Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients from 0% to 100%. The Levetiracetam bar is notably higher than the Placebo bar.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.